Cerebral Stroke: An Introduction
Stroke is the fifth leading cause of death and physical disability in the USA. Its prevention, diagnosis, and interventions are for the most part up and coming fields that give us feeling of how far medical and scientific work have progressed. Intravenous thrombolysis (IT) and endovascular thrombectomy (EVT) are evidence-based treatments for adults with a blocked blood vessel (ischemic stroke). EVT intervention is better than tpA treatment because of faster recanalization and less risk of hemorrhage especially in large artery occlusions. EVT treatment options include: Catheter-directed thrombolysis (CDT), pharmacomechanical catheter-directed thrombolysis (PCDT), percutaneous aspiration thrombectomy (PAT), vena cava filter protection, venous balloon dilatation and venous stent implantation. The feasibility, safety, and outcome of all therapies need to be assessed in adults, children, and pregnant women who have had a stroke. The significance of neuroprotective investigations in murine and stroke patients should be deliberately checked. Stem cells, nanoformulations and electromagnetic fields (EMF) are helpful emerging therapeutic interventions that contribute to the treatment of stroke patients.
KeywordsStroke Thrombectomy Oxygen-glucose deprivation Stem cell tPA
AKT gratefully acknowledges the financial support provided by the Department of Science and Technology-Science Engineering Research Board (DST-SERB) (PDF/2016/002996/LS), New Delhi, India, and the Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, for providing facilities and support.
- 1.Kissela, B., Broderick, J., Woo, D., Kothari, R., Miller, R., Khoury, J., Brott, T., Pancioli, A., Jauch, E., Gebel, J., & Shukla, R. (2001, June 1). Greater Cincinnati/Northern Kentucky Stroke Study: Volume of first-ever ischemic stroke among blacks in a population-based study. Stroke, 32(6), 1285–1290.CrossRefGoogle Scholar
- 2.Rosamond, W. (2007). American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 115, e69–e171.CrossRefGoogle Scholar
- 6.Ribo, M., Montaner, J., Molina, C. A., Arenillas, J. F., Santamarina, E., & Alvarez-Sabín, J. (2004, December). Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thrombosis and Haemostasis, 92(06), 1146–1151.Google Scholar
- 9.Zhang, H., Park, J. H., Maharjan, S., Park, J. A., Choi, K. S., Park, H., Jeong, Y., Ahn, J. H., Kim, I. H., Lee, J. C., & Cho, J. H. (2017, December). Sac-1004, a vascular leakage blocker, reduces cerebral ischemia–reperfusion injury by suppressing blood–brain barrier disruption and inflammation. Journal of Neuroinflammation, 14(1), 122.CrossRefGoogle Scholar
- 18.Tripathi, A. K., Dwivedi, A., Pal, M. K., Rastogi, N., Gupta, P., Ali, S., BH, M. P., Kushwaha, H. N., Ray, R. S., Singh, S. K., & Duggal, S. (2014, December). Attenuated neuroprotective effect of riboflavin under UV-B irradiation via miR-203/c-Jun signaling pathway in vivo and in vitro. Journal of Biomedical Science, 21(1), 39.CrossRefGoogle Scholar